Ipsen (GB:0MH6) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Luminaria study, officially titled “A Multicenter Non-interventional Study for the Measurement of Scratch and Sleep Patterns Using the ADAM Sensor in Patients With Primary Biliary Cholangitis,” tracks how people with this rare liver disease scratch and sleep in daily life. It aims to better understand symptom burden, which can guide future drug development and support tools for patients.
The study uses the ADAM sensor, a wearable digital device that passively records movement linked to scratching and sleep patterns. Its purpose is to replace subjective recall with objective data, giving Ipsen clearer insight into how primary biliary cholangitis, or PBC, affects quality of life over time.
This is an observational cohort study with a forward-looking design, meaning patients are followed over a set period without any study drug being given. There is no randomisation or blinding involved, as the goal is measurement rather than testing the effect of a specific treatment.
The trial began enrolling after initial submission on 9 June 2025, with each patient followed for about 91 days to capture stable scratch and sleep patterns. The study is now listed as completed, and the latest update on 31 March 2026 signals that Ipsen has locked key data and is preparing or refining its analysis.
For investors, this update suggests Ipsen is building a robust digital evidence base in PBC symptoms, which can support differentiation of current and future liver disease assets. Strong real-world style data on itch and sleep may help in payor talks, labelling discussions, and lifecycle management, especially as competitors also lean into digital endpoints across rare liver and autoimmune diseases.
The Luminaria study has been completed and recently updated, and further operational and scientific details remain available on the ClinicalTrials portal.
To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.